BioNexus targets 2026 initial VitaGuard MRD test rollout in Southeast Asia medical hubs
BGLC•Cost target
Management continues to plan for a cost per test below USD 300 before local pricing and reimbursement considerations.
License terms and market coverage
Execution will run under an exclusive license covering 10 Southeast Asian markets, with sublicensing permitted only with Fidelion’s prior written consent.
2026 rollout plan for VitaGuard MRD
BioNexus set 2026 targets to deploy the VitaGuard MRD liquid-biopsy platform in select Southeast Asian medical hubs, subject to local approvals.
Planning is underway to transfer and localize operating documentation, then complete laboratory verification and validation in Malaysia and Singapore.
